Kineta Announces Positive KVA12123 Monotherapy Safety and Bi

Kineta Announces Positive KVA12123 Monotherapy Safety and Biomarker Data from its Ongoing Phase 1/2 VISTA-101 Clinical Trial

03.10.2023 - Cleared First Three Monotherapy Cohorts with No Dose Limiting Toxicity and No Consistent Pattern of Adverse Events at any Dose Level

Related Keywords

Shawn Iadonato , Nasdaq , Kineta Inc , Chief Executive Officer , Kineta Chart , Ineta Kurs , Ineta Aktie ,